35 completed. 35 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 35 |
| Phase 2 | 1 | Completed 1 |
Follow Advanced Solid Malignancies: new trials by email Literature Review of Advanced Solid Malignancies trials Research Report on Advanced Solid Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies AZD5305, Itraconazole - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 16 | 2022-11-07 | 2024-06-18 |
| An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies Ceralasertib - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 12 | 2022-06-09 | 2024-08-02 |
| A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies YH002 - Advanced Solid Malignancies | Phase 1 | Completed | Eucure (Beijing) Biopharma Co., Ltd | 15 | 2020-04-22 | 2022-07-22 |
| A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies AZD4635 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 10 | 2019-07-04 | 2020-12-08 |
| A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients MEDI9447 (oleclumab) - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 6 | 2018-11-07 | 2019-07-08 |
| Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies AZD9150, Durvalumab - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 11 | 2018-01-30 | 2019-06-24 |
| Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies CT7001, Fulvestrant - Advanced Solid Malignancies | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 124 | 2017-11-14 | 2026-06-23 |
| A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies AZD4635, Durvalumab, Abiraterone Acetate - Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | AstraZeneca | 313 | 2016-06-17 | 2023-05-26 |
| Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment MPT0E028 - Advanced Solid Malignancies | Phase 1 | Completed | Taipei Medical University | 23 | 2015-04-24 | 2019-04-11 |
| A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies Fluzoparib - Advanced Solid Malignancies | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 79 | 2015-04-01 | 2019-06-17 |
| Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies AZD2014 - Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 28 | 2015-03-17 | 2024-12-17 |
| Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours AZD8835, AZD8835 in combination with fulvestrant - Advanced Solid Malignancies, Breast Cancer - ER+, HER2 - | Phase 1 | Completed | AstraZeneca | 20 | 2014-11-01 | 2016-10-10 |
| Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas Gemcitabine HCl Oral Formulation - Advanced Solid Malignancies, Malignant Lymphomas | Phase 1 | Completed | InnoPharmax Inc. | 37 | 2013-04-01 | 2019-07-08 |
| Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies olaparib - Cancer, Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 23 | 2013-03-25 | 2018-01-16 |
| Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma AZD1208 - Advanced Solid Malignancies, Malignant Lymphoma | Phase 1 | Completed | AstraZeneca | 43 | 2012-07-01 | 2015-11-04 |
| Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer AZD6244 - Neoplasms,, Metastatic Cancer, | Phase 1 | Completed | AstraZeneca | 33 | 2012-06-01 | 2016-10-21 |
| Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects MEDI-573 - Cancer, Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 10 | 2011-07-01 | 2014-12-11 |
| Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors HM781-36B tablets - Advanced Solid Malignancies | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 20 | 2011-06-01 | 2013-05-23 |
| Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies MLN0128, paclitaxel, trastuzumab - Advanced Solid Malignancies, Hematologic Malignancies | Phase 1 | Completed | Millennium Pharmaceuticals, Inc. | 68 | 2011-02-28 | 2019-08-08 |
| Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient AZD4547 - Cancer, Advanced Solid Malignancies | Phase 1 | Completed | AstraZeneca | 40 | 2010-11-01 | 2016-06-29 |
Showing 20 of 35. Sign in to see all of them.
Neoplasms (12) · Carcinoma, Non-Small-Cell Lung (2) · Lymphoma (2) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Hematologic Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1)
Neoplasms (6) · Neoplasms by Site (6) · Hemic and Lymphatic Diseases (3) · Neoplasms by Histologic Type (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Genital Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lung Diseases (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Respiratory Tract Diseases (2)
Fulvestrant (2) · Irinotecan (2) · durvalumab (2) · olaparib (2) · sapanisertib (2) · vistusertib (2) · (5-(2,4-bis((3S)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol (1) · 2-amino-7-(4-fluoro-2-(6-methoxypyridin-2-yl)phenyl)-4-methyl-7,8-dihydropyrido(4,3-d)pyrimidin-5(6H)-one (1) · 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide (1) · 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one (1) · AZD 6244 (1) · AZD 8931 (1) · AZD1208 (1) · AZD4547 (1) · AZD5305 (1)
AstraZeneca (20) · Hanmi Pharmaceutical Company Limited (3) · Millennium Pharmaceuticals, Inc. (2) · Novartis Pharmaceuticals (2) · Carrick Therapeutics Limited (1) · Eucure (Beijing) Biopharma Co., Ltd (1) · InnoPharmax Inc. (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Mayo Clinic (1) · Regeneron Pharmaceuticals (1) · Samyang Biopharmaceuticals Corporation (1) · Taipei Medical University (1)
Japan (13) · United States (7) · South Korea (4) · United Kingdom (4) · China (3) · Spain (2) · Taiwan (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Moldova (1) · Netherlands (1) · Romania (1) · Russia (1)
Charles Erlichman, M.D. (1) · Chia-Chi Lin, MD (1) · Dr. Udai Banerji (1) · Edward Bradley, MD (1) · Elisabeth Oelmann (1) · Frank Neumann, MSD (1) · Helen Lin (1) · Hendrik-Tobias Arkenau, FRCP, PhD (1) · Hideo Saka, MD, PhD (1) · Hideo Saka, Medical Doctor (1) · Ian Smith (1) · Ian Smith, Medical Science Director (1) · James Carmichael (1)
PMID 22145984, PMID 22843211, PMID 23010851, PMID 23589215, PMID 25342141, PMID 26223436, PMID 28070720, PMID 28601972, PMID 32385714, PMID 32913286, PMID 36270753, PMID 37488191, PMID 38086998, PMID 41351730
2009 (2), 2008 (1), 2017 (1)